ABSTRACT
OBJECTIVE: To analyze the incidence rate of repeat transurethral prostatectomy (TURP) and its probable causes after TURP for benign prostatic hyperplasia (BHP). METHODS: A retrospective study was conducted to summarize the cases who received repeat transurethral resection of prostate after TURP for benign prostatic hyperplasia in recent 20 years. The data were compared with the data of the cases who just received once TURP for BPH. RESULTS: 1225 patients received TURP for BHP from 1981 to 2001. Fifty-seven patients experienced repeat transurethral resection of the prostate after a mean interval of 3 years and 2 months with an incidence rate of 4.65%. 69.8% of which manifested repeat gross hematuria before repeat prostatectomy, with a rate significantly higher than the general gross hematuria rate and the gross hematuria rate at the first admission (P < 0.005 and P < 0.01). CONCLUSION: The incidence rate of repeat prostatectomy after TURP for BHP is 4.65%. The mean interval between the two procedures is 3 years and 2 months. Gross hematuria is one of the main causes for repeat TURP besides the low urinary tract symptoms.
Subject(s)
Postoperative Complications , Prostatectomy/adverse effects , Prostatic Hyperplasia/surgery , Aged , Aged, 80 and over , Humans , Male , Middle Aged , Reoperation , Retrospective Studies , Time Factors , Transurethral Resection of Prostate/methodsABSTRACT
OBJECTIVE: To investigate the expression of telomerase in various lesions of adrenal cortex. METHODS: By autoradiography-based telomeric repeat amplification protocol, telomerase expression was detected in 36 samples of adrenocortical lesions, including 29 cases adrenocortical adenoma (8 Cushing's syndrome, 17 aldosteronism and 4 nonfunctional adenomas), 5 cases of hyperplasia of adrenal cortex (presented with Chushing' syndrome), 2 cases adrenocortical carcinoma, and 4 samples of normal adrenal cortex. RESULTS: Of the 40 samples, 2 cases of adrenocortical carcinomas had telomerase expression, and the others had no telomerase expression detected. CONCLUSIONS: No significant telomerase expression was found among different endocrine functional benign adrenocortical lesions. Telomerase expression may be used as an important marker of malignant adrenocortical tumor.
